#targeted therapy

What Is Targeted Therapy?

KRAS has been one of the most hard-to-hit targets in cancer research.

Women who received a combination of Kisqali and hormone therapy lived twice as long without their cancer getting worse.

Targeted therapy combo sent chronic lymphocytic leukemia into deep remission in people with high-risk forms of the disease.

Adding an AKT inhibitor to fulvestrant doubled progression-free survival for patients with HR-positive, HER2-negative breast cancer.

The newer targeted therapy zanubrutinib works better and has fewer side effects than the older ibrutinib.

Research at #ASH22 calls into question longstanding assumptions and charts a path for gentler therapies.

Krazati led to tumor shrinkage in 43% of previously treated NSCLC patients with KRAS G12C mutations.

Research also showed that treatment before surgery benefits patients with HER2-low breast cancer.

Elahere, a new antibody-drug conjugate, shrank tumors in about a third of treatment-experienced patients.

The new approach takes advantage of the natural process by which cells break down proteins into fragments called peptides.

MatchMiner shortens the time it takes to identify appropriate precision medicine trials for individual patients.

Substituting generic, biosimilar or less expensive medications can reduce costs without sacrificing quality of care.

Treatment-experienced people who received the antibody-drug conjugate lived three months longer than those who got more chemotherapy.

The Phase III FRESCO-2 trial showed an improvement in progression-free survival.

Patients who added Cabometyx to Opdivo and Yervoy had a 27% lower risk of disease progression or death.

A micro-organosphere model of an individual patient’s cancer may help advance precision oncology.